Rationale for Correct Answer
The correct answer is: Dabrafenib plus trametinib
Dabrafenib plus trametinib is the only BRAF-MEK inhibitor combination that is FDA approved for use in metastatic NSCLC with a BRAF V600E mutation. The other combinations, encorafenib plus binimetinib and vemurafenib plus cobimetinib, are FDA approved therapies for BRAF-mutated melanoma.1 Dabrafenib plus trametinib is the National Comprehensive Cancer Network (NCCN)-preferred first line option for BRAF V600E mutated advanced NSCLC.2 Vemurafenib or dabrafenib monotherapies are not FDA approved for NSCLC but are considered useful in certain circumstances as first line therapies according to the NCCN guidelines.1,2
References:
1. U.S. Food & Drug Administration (FDA). Oncology (Cancer) / Hematologic Malignancies Approval Notifications. Reviewed June 20, 2023. Accessed June 20, 2023. https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm279174.htm
2. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer. Version 3.2023. Updated April 13, 2023. Available at: https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1450